Roche Hits A Wall With Its Tarceva Patent Claims In India; Novartis Moves Supreme Court For Glivec Rights
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - For the two Swiss drug giants Novartis and Roche, there was much action at India's Supreme Court Aug. 28 as they separately continued the fight to safeguard patents on their life-saving oncology drugs steadfastly challenged by health activists and generic drug manufacturers alike in India
You may also be interested in...
India’s Latest Patent Brawl Takes Another Twist As Natco Challenges BMS
Natco claims its product does not infringe on Bristol’s patent for Sprycel, and that it did not defy a court order by launching its product in India.
Did Natco Blunder In Launching Sprycel Copies In India? Patent Experts Debate Pros And Cons
By allegedly violating court injunctions, Natco may have negated its chance for a win against Bristol-Myers Squibb in a key pharmaceutical patent case.
Patent Blow: Roche Loses Tarceva Patent Infringement Case To Mylan’s India Unit Matrix Labs
The case could also spell the end of “forum shopping” in India, according to legal experts.